Compare ETO & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETO | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.2M | 472.9M |
| IPO Year | 2004 | 2015 |
| Metric | ETO | ZVRA |
|---|---|---|
| Price | $27.09 | $9.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 42.1K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $7.21 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $21.05 | $6.19 |
| 52 Week High | $31.11 | $13.16 |
| Indicator | ETO | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 53.53 |
| Support Level | $26.02 | $8.29 |
| Resistance Level | $27.67 | $9.72 |
| Average True Range (ATR) | 0.59 | 0.39 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 53.46 | 69.83 |
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas and consumable fuels, personal products, and other areas.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.